Stryker Q3 2026: 7.7% organic growth, adjusted EPS $3.52 misses consensus
Stryker grew organic sales 7.7% to $6.52 billion and lifted adjusted EPS 10.3% to $3.52 in Q3 2026, but the quarter fell short of management's own expectations and adjusted EPS missed the $3.58 consensus. GAAP EPS of $1.96 looks ugly mainly because of a $293 million goodwill impairment. Read the adjusted numbers for the business, the GAAP numbers for what the charges actually cost.
1 · Expected vs. Actual
Free preview belowGAAP EPS fell 11.7% to $1.96, and $293 million of goodwill impairment — $0.76 a share — explains most of the drop. Adjusted EPS rose 10.3% to $3.52, which still landed below the $3.58 consensus. Adjusted net earnings of $1.36 billion were up 10.1%, with the adjusted operating margin at 26.2%, up 60 basis points.
Revenue of $6.52 billion rose 7.7% from $6.06 billion a year earlier, and all of it was organic — currency added nothing. MedSurg and Neurotechnology did the heavy lifting at $3.66 billion, up 9.2%, while Orthopaedics grew 5.7% to $2.86 billion. Note the step down from $6.59 billion in Q2, and the CEO's own admission that the quarter fell short of internal expectations.
Log in to read 35 analyses a week for free
Create a free account to read 35 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-11-03
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.